ClinicalTrials.gg
RecruitingNCT07287150InavoPCUpdated Nov 6, 2026

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Inavolisib and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, sponsored by Hoffmann-La Roche. Recruiting at 50 sites in 12 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 6, 2026Eligibility revised4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche — 3 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Hoffmann-La Roche.

Planned enrollment
5th of 11
100 · median 84
Started
2026
with 1 other
Phase 2
3 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 2, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without small-cell or neuroendocrine features
  • Progressive CRPC, defined as any of the following: PSA progression, defined by a minimum of two rising PSA values from three consecutive assessments with an interval of at least 7 days between assessments and with a minimal starting value of PSA >=1 ng/mL; The most recent qualifying PSA value must be determined within 14 days of enrollment; Soft tissue disease progression, defined by , Version 1.1 (RECIST v1.1); Bone disease progression, defined by PCWG3 criteria, with two or more new metastatic bone lesions on a whole-body radionuclide bone scan
  • Treatment with at least one, but no more than one, prior second-generation ARPi (abiraterone, apalutamide, enzalutamide, darolutamide) for at least 12 weeks for HSPC or CRPC
  • Availability of a tumor tissue specimen that is suitable (e.g., adequate quality and quantity) for use in determining biomarker status
  • (ECOG) Performance Status of 0 or 1
  • Fasting glucose \<126 mg/dL and \< 6%

Exclusion criteria

Exclusion Criteria:

  • Presence of liver
  • Prior treatment with any phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT), or mammalian target of rapamycin (mTOR) inhibitor, or with any agent with a mechanism of action of inhibiting the PI3K/AKT/mTOR pathway
  • Type 1 or Type 2 diabetes mellitus
  • Prior treatment for mCRPC with cytotoxic chemotherapy or novel hormonal treatments (e.g., androgen receptor degraders, CYP11 inhibitors), with the following treatments permitted: Prior docetaxel in mHSPC, providing no evidence of disease progression occurred during treatment or within 6 months of treatment completion; Prior docetaxel in the or neoadjuvant setting providing no evidence of disease progression occurred during treatment or within 12 months of treatment completion; Prior treatment with sipuleucel-T, with the last dose administered >28 days prior to start of treatment; Prior PARPi therapy, as per local prescribing information, with the last dose administered >14 days prior to start of treatment; One prior RLT or radiotherapeutic agent (e.g., PSMA-targeted RLT, Radium 223) with the last dose administered >8 weeks prior to start of treatment
  • Other concurrent anti-cancer therapy except for androgen deprivation therapy
  • Treatment with strong CYP2C8 inhibitors, strong or moderate CYP2C8 inducers, or strong inducers within 1 week or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment
  • Transfusion of any blood product for the sole purpose of making a potential participant eligible for study inclusion or within 28 days of enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Participants will receive Inavolisib plus enzalutamide

    Drug: Inavolisib · Drug: Enzalutamide

  • Active comparator
    Arm 2

    Participants will receive either ARPi switch (enzalutamide or abiraterone) or docetaxel

    Drug: Enzalutamide · Drug: Abiraterone · Drug: Docetaxel

Interventions

  • Inavolisib will be administered orally as per the schedule specified in the protocol.

  • Enzalutamide will be administered orally as per the schedule specified in the protocol.

  • Abiraterone will be administered orally as per the schedule specified in the protocol.

  • Docetaxel will be administered intravenously as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Percentage of Participants with Confirmed Composite Response Rate (RR)

    Time frame: Up to approximately 5 years

  2. Percentage of Participants with Confirmed Prostate-Specific Antigen 90 (PSA90)

    Time frame: Up to approximately 5 years

  3. Percentage of Participants with Confirmed Prostate-Specific Antigen 50 (PSA50)

    Time frame: Up to approximately 5 years

  4. Objective Response Rate (ORR)

    Time frame: Up to approximately 5 years

  5. Duration of Response (DOR)

    Time frame: Up to approximately 5 years

  6. Overall Survival (OS)

    Time frame: Up to approximately 5 years

  7. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 5 years

07

Study locations

50 of 50 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 24 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 17, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Jul 30, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 2 sites removed
Show 4 added (2 United States, 1 Australia, 1 Italy)
  • University of Colorado Cancer Center · Aurora, United States
  • Grand Strand Regional Medical Center · Myrtle Beach, United States
  • Royal Brisbane & Women's Hospital · Herston, Australia
  • Istituto Oncologico Veneto - Sede di Castelfranco Veneto c/o Ospedale San Giacomo Apostolo · Castelfranco Veneto, Italy
Show 2 removed
  • Carolina Urologic Research Center · Myrtle Beach, United States
  • Royal Brisbane & Womens Hospital · Herston, Australia
Nov 6, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedTreatment with at least one, but no more than one, prior second-generation ARPi (abiraterone, apalutamide, enzalutamide, darolutamide) for hormone- sensitive prostate cancer (at least 12 weeks for HSPC) or CRPC
  • EditedFasting glucose <100126 mg/dL and HbA1c < 5.76%
Oct 8, 2026
Show all 3 updates
  1. Nov 6, 2026
    4 sites added, 2 sites removed
    Show 4 added (2 United States, 1 Australia, 1 Italy)
    • University of Colorado Cancer Center · Aurora, United States
    • Grand Strand Regional Medical Center · Myrtle Beach, United States
    • Royal Brisbane & Women's Hospital · Herston, Australia
    • Istituto Oncologico Veneto - Sede di Castelfranco Veneto c/o Ospedale San Giacomo Apostolo · Castelfranco Veneto, Italy
    Show 2 removed
    • Carolina Urologic Research Center · Myrtle Beach, United States
    • Royal Brisbane & Womens Hospital · Herston, Australia
    + 1 other change: verification date
  2. Oct 8, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedTreatment with at least one, but no more than one, prior second-generation ARPi (abiraterone, apalutamide, enzalutamide, darolutamide) for hormone- sensitive prostate cancer (at least 12 weeks for HSPC) or CRPC
    • EditedFasting glucose <100126 mg/dL and HbA1c < 5.76%
  3. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287150
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Mar 11, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Reference Study ID Number: CO45813 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion